Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

July 15, 2021

Study Completion Date

July 20, 2021

Conditions

COVID 19

Interventions

DRUG

HLX71

Single-dose, intravenous infusion

OTHER

Placebo

Single-dose, intravenous infusion

Trial Locations (1)

Frontage Clinical Services, Inc., Secaucus